SmileLines » Research updates

Big Birthday News

mwillis4 — Wed, 20 Oct 2010 20:57:36 +0000

Happy Ninth birthday Nolan and Jack! And to go along with your celebration, Glaxo Smith Kline announced today that it will be providing and additional $7 million dollars in funding to Prosensa for it’s continuing work on PRO051, an exon skipping drug which could change Duchenne!

Please believe,

Matt

BIG NEWS: Prosensa Exon Skipping Therapy Closing In!

mwillis4 — Sat, 07 Nov 2009 04:06:34 +0000

It was announced this week that human clinical trials of the exon skipping drug PRO051 will begin early next Spring in a collaborative effort between Prosensa and GlaxoSmithKline. The trials will take place in Columbus, Ohio starting in March, 2010 and will involve direct injection therapy as well as intravenous therapy in a double blind placebo format to further the efficacy and dosing parameters for the compound as well as broaden research data on recipients of the drug. Contact with a researcher involved in establishing the trial has been made and it is our every intention to involve Nolan and Jack in the trial if at all possible. This therapy has long been thought to be extremely viable and has proven reliable in both computer, animal, and preliminary human trials. Please follow the link below to the press release which highlights this development and keep hoping for this miracle to come true!

http://prosensa.eu/news/Press%20Release%20GSK%20-%20Prosensa.pdf

Continued smiles,

Matt

Duchenne care makes the NY Times frontpage

mwillis4 — Fri, 22 Feb 2008 19:01:06 +0000

This week the New York Times published an article bringing to light the constant struggles facing all Duchenne patients and their families. The article brings much needed national attention to the disease. I’ve posted the link below, please take some time and read it.

Matt

Lacking Cure, a New Tack on a Muscle Disease (New York Times)